- Home
- HPQ vs ONC Comparison
HPQ vs ONC Comparison
Compare HPQ & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPQ
- ONC
- Stock Information
- Founded
- HPQ 1939
- ONC 2010
- Country
- HPQ United States
- ONC Switzerland
- Employees
- HPQ N/A
- ONC N/A
- Industry
- HPQ Computer Manufacturing
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- HPQ Technology
- ONC Health Care
- Exchange
- HPQ Nasdaq
- ONC Nasdaq
- Market Cap
- HPQ 23.9B
- ONC 26.9B
- IPO Year
- HPQ N/A
- ONC N/A
- Fundamental
- Price
- HPQ $24.89
- ONC $245.58
- Analyst Decision
- HPQ Hold
- ONC Strong Buy
- Analyst Count
- HPQ 12
- ONC 7
- Target Price
- HPQ $30.46
- ONC $326.43
- AVG Volume (30 Days)
- HPQ 9.1M
- ONC 368.4K
- Earning Date
- HPQ 05-28-2025
- ONC 05-07-2025
- Dividend Yield
- HPQ 4.65%
- ONC N/A
- EPS Growth
- HPQ N/A
- ONC N/A
- EPS
- HPQ 2.61
- ONC N/A
- Revenue
- HPQ $54,298,000,000.00
- ONC $4,180,740,829.00
- Revenue This Year
- HPQ $3.37
- ONC $32.78
- Revenue Next Year
- HPQ $1.95
- ONC $19.07
- P/E Ratio
- HPQ $9.54
- ONC N/A
- Revenue Growth
- HPQ 2.45
- ONC 52.09
- 52 Week Low
- HPQ $21.21
- ONC $141.31
- 52 Week High
- HPQ $39.80
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- HPQ 35.04
- ONC N/A
- Support Level
- HPQ $23.59
- ONC N/A
- Resistance Level
- HPQ $28.47
- ONC N/A
- Average True Range (ATR)
- HPQ 0.74
- ONC 0.00
- MACD
- HPQ -0.39
- ONC 0.00
- Stochastic Oscillator
- HPQ 22.07
- ONC 0.00
About HPQ HP Inc.
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.